DDFPe in Acute Ischemic Stroke, a Phase Ib/II Clinical Trial

Download Adobe Acrobat Reader DocumentThe results of a randomized, blinded, placebo-controlled clinical trial testing intravenous DDFPe in patiets with acute ischemic stroke are presented. 6 patients received placebo, six patients received 0.05 ml/kg of DDFPe every 90 minutes for three doses, six patients received 0.10 ml/kg of DDFPe every 90 minutes for three doses, and six patients received 0.17 ml/kg of DDFPe every 90 minutes for three doses. IV DDFPe appeared safe at all tested doses. No MTD was defined. Exploratory Aims suggest that early DDFPe treatment improves NIHSS quickly and high dose DDFPe patients suggested improved outcomes. Larger trials are warranted.